New Regenerative Tissue Tech for Breast Reconstruction

Summary

ConneXio Sciences, now trading on the NASDAQ under ticker CNXU, is pioneering a regenerative medicine approach to tissue restoration, with a new technology called BREAST designed for post-mastectomy breast reconstruction. Unlike artificial implants or fat grafting, BREAST uses a temporary, bio-reabsorbable matrix made from natural ingredients to guide the body's own tissue to rebuild itself. This approach offers a potential alternative for women who have experienced complications with implants or were told reconstruction was impossible. The technology is part of a broader proprietary platform, CXU, which has applications in various medical fields including diabetes and neurology. ConneXio is currently seeking FDA clearance for wound healing applications using a bovine collagen-based version of CXU and plans to transition to human collagen. Following this, they aim for commercial adoption in aesthetics and then breast reconstruction, with the latter potentially requiring a more extensive PMA approval process. The company believes its diversified platform and strong team present a significant investment opportunity.